What the business is, and whether it's a good one at a fair price.
Manufactures and sells generic pharmaceutical finished dosage formulations (tablets, capsules and other oral solids), which made up 74% of consolidated revenue in Q1 FY27. The complex-generics portion of the finished-dosage book has risen to 50% (from 39% a year earlier), and the company now holds two Sole First-to-File ANDA approvals that grant 180-day US market exclusivity — Sodium Oxybate Extended-Release Oral Suspension (generic of LUMRYZ for narcolepsy) and Amphetamine Extended-Release Tablets. Alongside finished dosages, it makes Active Pharmaceutical Ingredients (13% of Q1 FY27 revenue), Pharma Formulation Intermediates (9%), and runs a peptide Contract Development and Manufacturing Organization through the acquired Senn Chemicals AG, which grew more than 100% year-on-year and contributed 4% of revenue. Manufacturing spans eight facilities; seven have a clean Establishment Inspection Report from the USFDA, with 9 product launches and 25 ANDAs sitting behind the Gagillapur facility's pending reinspection. R&D spending ran at about 6% of sales in Q1 FY27, and FY27 capex is guided at ₹600 crore, including roughly ₹300 crore phased over multiple years for a peptide intermediates and API plant in India.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from GRANULES INDIA LIMITED's filed financials and exchange disclosures
GRANULES INDIA LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol GRANULES.
Yes. Over the trailing twelve months GRANULES INDIA LIMITED reported a net profit of ₹662 Cr on revenue of ₹5,632 Cr.
Yes. The dividend yield is 0.16% at the current price. It paid out 6% of its profit as dividend in FY26.
No. Debt stands at 0.26× equity, and it carries net debt of ₹458 Cr. That is lower than 34% of its 171 Pharmaceuticals peers.
On trailing P/E, GRANULES INDIA LIMITED ranks 93 of 169 in Pharmaceuticals — cheaper than 45% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session GRANULES INDIA LIMITED moves 0.98% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by GRANULES INDIA LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
